RxDoctor Payments DataLook up a doctor →

Bradley Torphy, MD

Family Medicine · Chicago, ILNPI 1104052372

Payments from drug & device makers

$2,970,541in general payments, 2019–2025

Across 2,408 payments — averaging $1233.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1.6M
  • Amgen$350K
  • Teva Pharmaceuticals USA, Inc.$209K
  • Eli Lilly$188K
  • Lilly USA, LLC$150K
  • Pfizer$107K
  • plus $328K from 25 others
$24,328in research payments, 2019–2025

Across 7 payments — averaging $3475.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$13K
  • Pfizer$10K
  • Eli Lilly$1K

What the payments were for

  • Consulting fees$134,78410%
  • Speaking & faculty fees$1,098,82082%
  • Grants$420%
  • Travel & lodging$75,2976%
  • Food & beverage$38,2593%
  • Education$4450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,970,541 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$94,963
Medicare patients
68
Services billed
10,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant19$28,641
Emgality PenGalcanezumab-Gnlm27$18,823
QuliptaAtogepant11$18,128
Ajovy AutoinjectorFremanezumab-Vfrm21$16,644
Aimovig AutoinjectorErenumab-Aooe11$15,307
Sumatriptan Succinate34$9,474
Gabapentin31$416
Acetazolamide19$407
Venlafaxine Hcl ErVenlafaxine Hcl17$316
Divalproex Sodium13$251
Topiramate28$179
Memantine Hcl11$166
Baclofen28$101
Diphenhydramine Hcl11$86
Hydroxyzine Hcl13$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,637,925$46,76930 claims
Upsher-smith Laboratories LLCTopiramate$638$17928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →